期刊文献+

血浆高密度脂蛋白胆固醇水平对冠脉介入治疗术后1年不良事件的预测价值 被引量:1

Usefulness of Serum High-Density Lipoprotein Cholesterol Level as a Predictor of One-year Adverse Events after Percutaneous Coronary Interventions
原文传递
导出
摘要 目的:探讨冠脉介入治疗(PCI)术后1年不良心血管事件与高密度脂蛋白胆固醇(HDL-C)水平变化的关系。方法:本研究收集2009年1月至2010年1月我科收治的435例冠心病且接受PCI治疗患者的一般资料、PCI术后1年随访临床终点,按HDL-C水平分为三组:HDL-C>1.55 mmol/L,HDL-C 1.04-1.55 mmol/L,HDL-C<1.04/L,比较组间1年临床结果差异,并用多元回归方法分析PCI术后1年死亡的影响因素。结果:HDL-C水平的更低患者相对年轻(69.3±9.5 vs 65.5±9.2 vs 62.8±9.2,p=0.007),同时合并吸烟(14.5%vs 13.0%vs 24.6%,p=0.002)、糖尿病(23.4%vs 27.8%vs 36.6%,p=0.019)、LVEF<30%(2.4%vs 5.3%vs4.9%,p=0.020),接受急诊PCI比例更高(4.8%vs 6.5%vs 7.0%,p=0.034);且PCI术后1年死亡(2.4%vs 2.4%vs 6.3%,p=0.008)、再血管化(20.2%vs 21.9%vs 25.4%,p=0.022)、再次心源性入院(30.6%vs 32.0%vs 37.3%,p=0.013)、术后6m内心绞痛复发(20.2%vs 20.1%vs 22.5%,p=0.038)的比例均更高。结论:HDL-C<1.04 mmol/L是导致冠心病患者接受PC术后1年死亡的独立危险因素。 Objective: To analyze the relationship between One-Year Adverse Events After Percutaneous Coronary Interventions and Serum High-Density Lipoprotein Cholesterol Level. Methods: In a sample of 435 patients who underwent PCI, we evaluated 1-year mortality, acute myocardial infarction and repeat revascula- rization as a function of baseline HDL levels classified into approximate quartiles of HDL-C 〉1.55 mmol/1,HDL-C 1.04-1.55 retool/1 and HDL-C 〈1.04 mmol/1. Results: Decreasing levels of HDL cholesterol were associated with younger age (69.3+ 9.5 vs 65.5:1:9.2 vs 62.8+ 9.2, p=0.007), smoking (14.5% vs 13.0% vs 24.6%, p--0.002), diabetes mellitus (23.4% vs 27.8% vs 36.6%, p=0.019), LVEF〈30% (2.4% vs 5.3% vs 4.9%, p=0.020) and emergent PCI (4.8% vs 6.5% vs 7.0%, p=0,034). Furthermore, One-year mortality (2,4% vs 2.4% vs 6.3%,p=0.008), coronary revascularization (20.2% vs 21.9% vs 25.4%,p=0.022), readmission (30.6% vs 32.0% vs 37.3%,p=0.013) and repeated angina (20.2% vs 20.1% vs 22.5%,p=0.038)were significantly higher in the patients with decreased HDL-C level. Conclusion: In patients with coronary artery disease undergoing PCI, a baseline HDL-C 〈1.04 mmol/1 is an important prognostic indicator.
出处 《现代生物医学进展》 CAS 2012年第28期5558-5561,共4页 Progress in Modern Biomedicine
关键词 高密度脂蛋白胆固醇 冠脉介入治疗 预后 High-Density Lipoprotein Cholesterol Percutaneous Coronary Inter- ventions prognosis
  • 相关文献

参考文献15

  • 1Castelli WP, Garrison ILl, Wilson PW, et al. Incidence of coronary he- art disease and lipoprotein cho- lesterol levels. The Framingham Study [J]. JAMA 1986,256:2835-2838.
  • 2Weintraub WS, Clements SD Jr, Crisco LV-T, et al. Twenty-year surv- ival aider coronary artery surgery: an institutional perspective from Em- ory University[J]. Circulation, 2003, 107:1271-1277.
  • 3Gordon D J, Probstfield JL, Garrison R J, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American stu- dies[J]. Circulation ,1989,79:8-15.
  • 4Barter P, Gotto AM, LaRosa JC, Maroni J, et al. for Treating to New Targets I. HDL cholesterol, very low levels of LDL cholesterol, and cardiovas-cular events[J]. N Engl J Med, 2007, 357:1301-1310.
  • 5Lundstam U, Herlitz J, Karlsson T, et al. Serumlipids, lipoprotein(a) l- evel, and apolipoprotein(a) isoforms as prognos- tic markers in patients with coronary heart disease[J]. J Intern Med, 2002, 251:111-118.
  • 6Amit V. Khera, Marina Cuehel, Margarita Llera-Moya, Cholesterol El- flux Capacity, High-Density Lipoprotein Function, and Atherosclerosis [J]. N Engl J Med, 2011,364(2):127-135.
  • 7Nerses S, Jeffrey LS, Mohamad N, et al. High-Density Lipoprotein Cholesterol An Emerging Target for Stroke Treatment [J]. Stroke, 2007, 38:1104-1109.
  • 8邓捷,韩雅玲,王效增,荆全民,王守力,马颖艳.高密度脂蛋白胆固醇水平降低对非ST段抬高型急性冠状动脉综合征介入治疗预后的影响[J].中国介入心脏病学杂志,2008,16(5):251-254. 被引量:3
  • 9Gotto AM Jr, Brinton EA. Assessing low levels of high-density lipo-pr- otein cholesterol as a risk factor in coronary heart disease: a work- ing group report and update[J]. J Am Coil Cardiol, 2004, 43( 5):717 -724.
  • 10Goldenberg I, Goldbourt U, Boyko V, et al. Relation between on-trea- tment increments in serum high- density lipoprotein cholesterol levels and cardiac mortality in patients with coronary heart disease (from th- e Bezafibrate Infarction Preven-tiontrial) [J]. Am J Cardiol, 2006, 97: 466-471.

二级参考文献15

  • 1陈征,华琦.冠状动脉病变与血脂代谢异常的相关性[J].中国介入心脏病学杂志,2005,13(2):100-102. 被引量:9
  • 2Lavie CJ, Milani RV. Shedding Light on High-Density Lipoprotein Cholesterol: The Post-ILLUMINATE Era. J Am Coll Cardiol,2008,51 ;56-58.
  • 3Ford ES, Giles WH, Dietz WH, et al. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA,2002,287:356- 359.
  • 4Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome : an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation, 2005,112:2735-2752.
  • 5Roel MT, Fang-Shu Ou, Karen P, et al. Patterns and prognostic implications of low high-density lipoprotein levels in patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J, 2008,0 : ehnvi-9.
  • 6Chapman M J, Assmann G, Fruchart JC, et al. Raising high- density lipoprotein cholesterol with reduction of cardiovascular risk : the role of nicotinic acid a position paper developed by the European Consensus Panel on HDL-C. Curt Med Res Opin, 2004,20 : 1253-1268.
  • 7Gordon DJ, Rifkind BM. High-density lipoprotein the clinical implications of recent studies. N Engl J Med, 1989,321 : 1311- 1316.
  • 8Castelli WP, Garrison RJ, Wilson PW, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Studv..IAMA. 1986. 256, 2835-2838.
  • 9Olsson AG, Schwartz GG, Szarek M, et al. High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. Eur Heart J, 2005,26:890-896.
  • 10Roswitha MW, Brewer HB, Zhenyi Xue, et al. Impact of low high-density lipoproteins on in-hospital events and one-year clinical outcomes in patients with non-ST-elevation myocardial infarction acute coronary syndrome treated with drug-eluting stent implantation. Am J Cardiol, 2006,98:711-717.

共引文献2

同被引文献17

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部